user

Phase II trial of neoadjuvant osimertinib for surgically resectable EGFR-mutated non-small cell lung cancer

被引：0
|
作者：
Aredo, Jacqueline V.
Urisman, Anatoly
Gubens, Matthew A.
Mulvey, Claire
Allen, Greg M.
Rotow, Julia K.
Kerr, Daniel Lucas
Chakrabarti, Turja
Bacaltos, Bianca
Gee, Megan
Jones, Kirk
Aisner, Dara L.
Patil, Tejas
Schenk, Erin Lynn
Bivona, Trever G.
Riess, Jonathan W.
Coleman, Melissa
Kratz, Johannes Ruediger
Jablons, David
Blakely, Collin M.
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Univ Colorado, Aurora, CO USA
[4] Univ Colorado, Comprehens Canc Ctr, Aurora, CO USA
[5] Univ Colorado, Anschutz Med Campus, Aurora, CO USA
[6] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8508
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiation
    Mak, D. Y.
    Yan, M.
    Cheung, P.
    Parmar, A.
    Poon, I.
    Ung, Y.
    Tsao, M.
    Warner, A.
    Louie, A. V.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S497 - S497
  • [32] Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-Mutated Non-small Cell Lung Cancer
    Lee, Jiyun
    Shim, Joon Ho
    Park, Woong-Yang
    Kim, Hee Kyung
    Sun, Jong-Mu
    Lee, Se-Noon
    Ahn, Jin Seok
    Park, Keunchil
    Ahn, Myung-Ju
    CANCER RESEARCH AND TREATMENT, 2019, 51 (01): : 408 - 412
  • [33] Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
    Bertoli, Elisa
    De Carlo, Elisa
    Del Conte, Alessandro
    Stanzione, Brigida
    Revelant, Alberto
    Fassetta, Kelly
    Spina, Michele
    Bearz, Alessandra
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [34] Pathological assessment of osimertinib-associated cardiotoxicity in EGFR-mutated non-small cell lung cancer patients
    Oka, T.
    Kamada, R.
    Kunimasa, K.
    Oboshi, M.
    Nishikawa, T.
    Yasui, T.
    Shioyama, W.
    Miyashita, Y.
    Koyama, T.
    Kumagai, T.
    Fujita, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 881 - 881
  • [35] Survival mechanisms of osimertinib-tolerant persister cells in EGFR-mutated non-small cell lung cancer
    Haga, Yuya
    Nishimura, Akihide
    Higashisaka, Kazuma
    Tsutsumi, Yasuo
    CANCER SCIENCE, 2025, 116 : 1551 - 1551
  • [36] Targeting non-coding RNAs to overcome osimertinib resistance in EGFR-mutated non-small cell lung cancer
    Zeng, Beilei
    Gan, Kelun
    Yu, Yuanhang
    Hu, Jianping
    Deng, Qiao
    Yin, Chong
    Gao, Xi
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [37] Evaluation of Pneumonitis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Receiving Osimertinib and Thoracic Radiotherapy
    Mak, D. Y.
    Yan, M.
    Cheung, P.
    Parmar, A.
    Poon, I.
    Ung, Y. C.
    Tsao, M.
    Warner, A.
    Louie, A. V.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : E380 - E381
  • [38] Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Kim, H.
    Han, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1120 - S1120
  • [39] Final Overall Survival Results from the FLAURA Trial: a Phase III Study on Osimertinib in EGFR-Mutated Advanced Non-small Cell Lung Cancer
    Wang, Yue
    Nan, Juan
    JOURNAL OF INTERNATIONAL TRANSLATIONAL MEDICINE, 2020, 8 (02): : 27 - 29
  • [40] EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
    Buder, Anna
    Hochmair, Maximilian J.
    Setinek, Ulrike
    Pirker, Robert
    Filipits, Martin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 239 - +
12345